ReviewCureus2025
Lipidomic Profiling: A Promising New Direction in the Diagnosis and Management of Thyroid Cancer?
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Wooden-Tip Electrospray Ionization Mass Spectrometry Combined With Machine Learning for Differentiating Thyroid Tumours.Analytical science advances · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thyroid carcinoma (TC) is the most common endocrine malignancy worldwide, with an ongoing rise in its incidence. Despite improved diagnostic and therapeutic methods, distinguishing between benign and malignant nodules and predicting disease aggressiveness remains challenging. Lipidomics is a comprehensive approach to lipid profiling that is able to provide new insights into thyroid cancer biology. We conducted a methodical literature search for studies that looked into lipid metabolism alterations in the biofluids and tissue samples of TC patients and investigated the potential of the lipidomic fingerprint as a diagnostic or therapeutic target. Studies not employing lipidomic techniques, those using animal models, or focusing on other cancer types were excluded. The reviewed studies consistently revealed significant alterations in various lipid classes, including fatty acids (FA), phospholipids (PL), and sphingolipids (SL) across different sample types (serum, plasma, urine, and tissue) from TC patients compared to benign or healthy controls. Clinically, these findings provide a foundation for more accurate, non-invasive diagnostic tools and for classifying disease subtypes based on lipidomic signatures. For instance, modified glycerophospholipid (GPL) and SL species were observed in the plasma of thyroid cancer patients, and enhanced FA metabolism was correlated with tumor aggressiveness and poor prognosis. Lipidomics is a rapidly evolving field with tremendous potential for improving the clinical management of differentiated TC patients, from diagnosis to therapeutic intervention. The consistent identification of modified lipid profiles highlights their essential role in the metabolic reprogramming associated with tumorigenesis and also their importance as reliable clinical biomarkers. In order to implement routine clinical use of lipidomics, further large-scale validation studies are needed, along with standardized lipidomic protocols, to ensure reproducibility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.